Direct Comparison of Real-world Effectiveness of Biologics for Psoriasis using Absolute and Relative Psoriasis Area and Severity Index Scores in a Prospective Multicentre Cohort.

Acta Derm Venereol · 2022 · PMC9574692 · PMID 35356990

Europe PMC DOI

hedged sentence

0.0620

closest p · 1.2× alpha

0.0620

boldest claim

The sentences

nearly significantp = 0.062so close (0.05 < p ≤ 0.1)

Except for a nearly significant difference between the estimated mean PASI scores after 12 months in guselkumab vs ustekinumab ( p = 0.062), ixekizumab and guselkumab showed better results compared with the other biologics for both absolute and relative PASI outcomes.

also in 3,279 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.